/Companies

SUTROVAX, INC.

NASDAQ: PCVX

South San Francisco, US · Founded 2013 · 11 known investors

Find your way into SUTROVAX, INC.

Sign up to see every warm intro you have to SUTROVAX, INC.

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the SUTROVAX, INC. team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases. The company is led by experienced vaccinologists and pharma industry veterans.

Founders & leadership

SUTROVAX, INC. was founded in 2013 by Grant Pickering and Jeff Fairman.

GP
Grant PickeringChief Executive Officer, Director and Co-Founder
JF
Jeff FairmanVice President of Research and Co-Founder
AK
Ashish KhannaExecutive

Board

TS
Tracy SaxtonBoard director
WN
William NewellBoard director
KVKurt von Emster
Kurt von EmsterBoard directorManaging Partner at Abingworth
PEPatrick Enright
Patrick EnrightBoard directorManaging Director at Longitude Capital

Investors · 11

Reported raises · per SEC filings

Form D private placements

$205.9M disclosed across 4 rounds · 2015–2020

▶$110MraisedApr 2020 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeff FairmanExecutive Officer
  • William NewellDirector
  • Rob HopfnerDirector
  • Kurt von EmsterDirector
  • Peter HirthDirector
  • Jane Wright-MitchellExecutive Officer
  • Moncef SlaouiDirector
  • James P WassilExecutive Officer
  • Patrick EnrightDirector
  • Grant E PickeringExecutive Officer, Director
  • Patrick J HeronDirector
  • Heath LukatchDirector
Offering amount
$110M
Amount sold
$110M
First sale
Mar 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$43.2MraisedJun 2018 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William J NewellDirector
  • Peter HirthDirector
  • Durga P BobbaExecutive Officer
  • Elaine SunExecutive Officer
  • Jeff FairmanExecutive Officer
  • Grant E PickeringExecutive Officer, Director
  • Moncef SlaouiDirector
  • Heath LukatchDirector
  • Kurt von EmsterDirector
  • Patrick HeronDirector
  • Rob HopfnerDirector
  • Patrick EnrightDirector
Offering amount
$85.7M
Amount sold
$43.2M
First sale
May 2018
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$40.1MraisedMar 2017 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kurt von EmsterDirector
  • Patrick EnrightDirector
  • Elaine SunExecutive Officer
  • Peter HirthDirector
  • Grant PickeringExecutive Officer, Director
  • Patrick HeronDirector
  • Jeff FairmanExecutive Officer
  • Ashish KhannaExecutive Officer
  • Tracy SaxtonDirector
  • William NewellDirector
Offering amount
$60.2M
Amount sold
$40.1M
First sale
Mar 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.6MraisedJul 2015 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tracy SaxtonDirector
  • Grant E PickeringExecutive Officer, Director, Promoter
  • Jeff FairmanExecutive Officer
  • Ashish KhannaExecutive Officer
  • William NewellDirector
  • Kurt von EmsterDirector
  • Patrick EnrightDirector
Offering amount
$26.9M
Amount sold
$12.6M
First sale
Jul 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$774.2Mvaluation at IPOJun 2020 · $16.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$196.1K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does SUTROVAX, INC. do?
Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases. The company is led by experienced vaccinologists and pharma industry veterans.
Who founded SUTROVAX, INC.?
SUTROVAX, INC. was founded by Grant Pickering, Jeff Fairman in 2013.
Who are SUTROVAX, INC.'s investors?
SUTROVAX, INC.'s investors include Abingworth, CTI Life Sciences Fund L.P., Foresite Capital, Frazier Life Sciences, Janus Henderson Investors, Longitude Capital, Medicxi, Pivotal Life Sciences and 3 more.
How much funding has SUTROVAX, INC. raised?
SUTROVAX, INC. has disclosed $205.9M raised across 4 rounds.
Where is SUTROVAX, INC. headquartered?
SUTROVAX, INC. is headquartered in South San Francisco, US.